BLI-800-301: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
A Safety and Efficacy Evaluation of BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
1 other identifier
interventional
400
1 country
11
Brief Summary
This is a randomized, parallel, multi-center, single-blind study, comparing BLI-800 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jul 2007
Shorter than P25 for phase_3
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2007
CompletedFirst Submitted
Initial submission to the registry
July 17, 2007
CompletedFirst Posted
Study publicly available on registry
July 19, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2007
CompletedDecember 27, 2007
December 1, 2007
4 months
July 17, 2007
December 20, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy - preparation quality using a 4 point scale
2-Day
Secondary Outcomes (1)
Safety - preparation related side effects; laboratory analysis
30-Day
Interventions
Eligibility Criteria
You may qualify if:
- Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:
- Evaluation of BE results
- GI bleeding
- Anemia of unknown etiology
- Neoplastic disease surveillance
- Endosonography
- Inflammatory bowel disease
- Unknown diarrhea or constipation etiology
- Polypectomy
- Laser therapy
- Routine Screening
- At least 18 years of age
- Otherwise in good health, as determined by physical exam and medical history
- If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse)
- Negative urine pregnancy test at screening, if applicable
- +1 more criteria
You may not qualify if:
- Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
- Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
- Subjects who are undergoing colonoscopy for foreign body removal and decompression.
- Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.
- Subjects with a history of renal or hepatic insufficiency or congestive heart failure.
- Subjects who had previous gastrointestinal surgeries
- Subjects who are pregnant or lactating, or intending to become pregnant during the study.
- Subjects of childbearing potential who refuse a pregnancy test.
- Subjects who are allergic to any preparation components
- Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (11)
Unknown Facility
Mobile, Alabama, 36693, United States
Unknown Facility
Washington D.C., District of Columbia, 20010, United States
Unknown Facility
Jupiter, Florida, 33458, United States
Unknown Facility
Miami, Florida, 33143, United States
Unknown Facility
New Smyrna Beach, Florida, 32168, United States
Unknown Facility
Monroe, Louisiana, 71201, United States
Unknown Facility
Laurel, Maryland, 20707, United States
Unknown Facility
Great Neck, New York, 11023, United States
Unknown Facility
Raleigh, North Carolina, 27612, United States
Unknown Facility
Lancaster, Pennsylvania, 17604, United States
Unknown Facility
Chesapeake, Virginia, 23320, United States
Study Officials
- STUDY DIRECTOR
John D McGowan, BS
Braintree Laboratories, Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
July 17, 2007
First Posted
July 19, 2007
Study Start
July 1, 2007
Primary Completion
November 1, 2007
Study Completion
November 1, 2007
Last Updated
December 27, 2007
Record last verified: 2007-12